Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals End-of-Life care patterns for sarcoma patients

NCT ID NCT07532668

Knowledge-focused Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 207 adults who died from sarcoma to understand how they were cared for by palliative teams. Researchers looked at when patients first saw a palliative care doctor, were admitted to a palliative care unit, or received advice from a mobile palliative team. They also checked how many received chemotherapy in their last two weeks or visited the emergency room multiple times in their final month. The goal was to describe current care patterns, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

207 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with sarcoma follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie who died in 2024

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Oncology follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie * sarcoma histology confirmed * \>18 years at diagnosis * death between 01/01/2024 ans 31/12/2024 * death related to sarcoma Exclusion Criteria: * \>1 year between last follow up in Centre Léon Bérard, or Institut Gustave Roussy, or Institut Curie and death * patient opposed to the collect of data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Death neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoma

Contacts and locations

Locations

  • Centre Leon Berard

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.